What the FDA statement on unapproved GLP-1 drugs means for you

What the FDA statement actually says

The FDA's statement covers unapproved versions of GLP-1 receptor agonist drugs, including tirzepatide and semaglutide, that people are using for weight loss. The concern it names is specific: unapproved versions do not undergo the FDA review for safety, effectiveness and quality that an approved product goes through.

That is a description of a regulatory pathway, and it is accurate. Compounded medications are not FDA approved finished products. A licensed provider determines eligibility.

The statement groups several very different things under one heading, and it is worth separating them. Counterfeit products carrying false information on the label, including pharmacy names that do not exist. Salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the approved formulations. Products sold online with no prescription at all. Vials falsely labeled for research purposes or not for human consumption, sold directly to consumers for human use with dosing instructions anyway. And compounded preparations dispensed through state-licensed pharmacies on a prescription.

Those categories carry very different risks. FDA separates them too. The FDA's guidance to patients is to obtain a prescription from a licensed doctor, fill it at a state-licensed pharmacy, and ask who prepared the medication.

One line deserves to be read directly rather than summarized. FDA writes that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. That is a clinical judgment. It belongs to the licensed provider reviewing your history, and it is one of the things your intake exists to answer.

Where tirzepatide and semaglutide sit

Tirzepatide and semaglutide are approved molecules with a real clinical record behind them.

FDA approved Zepbound (tirzepatide) injection on November 08, 2023 for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter or greater) or overweight (body mass index of 27 kilograms per square meter or greater) with at least one weight-related condition, for use in addition to a reduced calorie diet and increased physical activity. In the trial enrolling participants without diabetes, those receiving the maximum dose lost on average 18% of their body weight compared to those randomized to placebo. Outcomes vary by individual and are not guaranteed. Semaglutide is an approved molecule as well, and Ozempic is among the approved products FDA names as a target of counterfeiting.

Here is the part that has to be said plainly. That trial record belongs to the approved product, at the doses and on the schedule that were studied. A compounded preparation is a different thing, and Belle says so on its own safety page: compounded tirzepatide is prepared by a licensed compounding pharmacy, is not evaluated by the FDA for safety or effectiveness, and is not equivalent to FDA-approved tirzepatide products such as Zepbound or Mounjaro.

Claiming that a compounded drug matches an FDA approved version is the first item on the FDA's list of telehealth red flags. It is a claim worth refusing to make.

Where the real risk is

For most people considering a GLP-1 medication, the largest risk is not the molecule. It is the channel.

A label that reads for research purposes only is not marketing filler. It is the legal line that lets a vendor sell a chemical without the oversight that applies to medicine. FDA names exactly that pattern: products falsely labeled for research purposes or not for human consumption, sold to people for human use with dosing instructions attached. Those sellers are not pharmacies, and there is no one standing behind the vial.

Two compounds that come up often in the GLP-1 conversation, retatrutide and cagrilintide, cannot be used in compounding under federal law. FDA states that they are not components of FDA approved drugs and have not been found safe and effective for any condition. Belle does not prescribe either one. If a company offers them, that is a signal worth noticing.

Dr. Taylor on the FDA statement

"I read this statement the way I read most safety communications, as a description of what happens when a medicine gets separated from a prescriber. Nearly everything FDA lists there is a sourcing failure, a labeling failure or a dosing failure, and every one of those is something a licensed provider and a licensed pharmacy exist to prevent. What I will not do is tell a patient that a compounded preparation is the same as the approved product, because it is not, and whether it is the right choice for that patient is a clinical judgment I make with them rather than an option they select."

Dr. Patrick Taylor, MD, Chief Medical Officer at Belle

What the adverse event reports describe

As of May 31, 2026, FDA had received more than 730 adverse event reports associated with compounded tirzepatide and 990 associated with compounded semaglutide. FDA also notes that federal law does not require every state-licensed pharmacy to submit adverse events to the agency, so the real number is likely higher.

What those reports describe matters as much as the count. FDA points to dosing errors, with patients measuring and self-administering incorrect doses and healthcare professionals miscalculating doses, some of which required hospitalization. It points to patients prescribed doses beyond what is in the FDA approved drug label, including higher single doses, more frequent dosing, or accelerated titration schedules. It points to storage, noting that injectable GLP-1 drugs require refrigeration as indicated in their package inserts, and that it received complaints about products arriving warm or with inadequate ice packs. And it points to multi-dose vials, which FDA recommends using within 28 days after first use because of increased contamination risk after that point.

None of that is a reason to avoid these medications. It is a reason to have a provider setting your dose, a pharmacy preparing it for you by name, and someone tracking your response, rather than dosing from a spreadsheet.

Who should talk to a provider first

• A personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy, plans to become pregnant, or active breastfeeding
• A history of a serious allergic reaction to tirzepatide or any of its ingredients
• Insulin, sulfonylureas, or medications with a narrow therapeutic index, which may need dose adjustment
• Any history of pancreatitis, gallbladder disease, kidney problems, or depression

Common side effects reported with these medications include nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, acid reflux, injection site reactions, fatigue, decreased appetite and hair loss. Tell your provider about every medication and supplement you take, so that list can be reviewed against your history.

How Belle prescribes tirzepatide and semaglutide

Belle offers compounded tirzepatide and compounded semaglutide as prescription medications. It begins with an online intake reviewed by a licensed provider, who decides whether a prescription is appropriate for you. If it is, the medication is prepared by a licensed United States compounding pharmacy and shipped with your name on the label. Belle partners exclusively with licensed United States compounding pharmacies, and all compounded medications dispensed through Belle are prepared in compliance with applicable state and federal regulations.

A prescription is never guaranteed. If a treatment is not appropriate for you, the answer is no, and that is the review working as intended.

Dosing is not one-size-fits-all. Your provider sets your dose and schedule after your medical intake and adjusts it as your treatment progresses. Changes are typically gradual rather than immediate, and side effects often ease as your body adjusts. Timelines and outcomes vary by individual, and your provider will monitor your progress and adjust your plan as needed.

The FDA's red flag list is genuinely useful, so use it. Be cautious with a company that claims its compounded drug matches the FDA approved version, that offers extreme price discounts, that ships medicine differing from previous orders or in damaged packaging with no instructions, that does not require screening and a prescription from a licensed doctor, that does not provide licensed doctor support after delivery, or that lists a pharmacy address or name that does not check out. If you can complete a checkout faster than you can describe your health, that is a signal worth noticing.

If something does go wrong, you can report it to FDA directly through the MedWatch Adverse Event Reporting program.

Nothing here is medical advice. Decisions about your own care belong with a licensed provider who knows your history.